Home/Oisin Biotechnologies/Matthew Scholz

MS

Matthew Scholz

Chief Executive Officer

Oisin Biotechnologies

Therapeutic Areas

Aging Frailty/Sarcopenia Metabolic Disease Senescence-associated disorders

Oisin Biotechnologies Pipeline

Drug	Indication	Phase
Muscle Growth Program	Frailty/Sarcopenia	Preclinical
Fat Cell Clearance Program	Obesity/Metabolic Dysfunction	Preclinical
Senescent Cell Clearance Program	Senescence-associated diseases	Preclinical

Leadership Team at Oisin Biotechnologies

John Lewis, Ph.D.

Chief Science Officer

Chief Operating Officer

Stephen Hilbert

Chief Business Officer

Henry Garcia, Ph.D.

Head of Aging R&D

Alexandre Gingras, Ph.D.

Head of Preclinical Manufacturing

View full Oisin Biotechnologies profile